Mohammed Awad, MD
Pulmonary Disease · Sioux Falls, SDNPI 1255818423
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (56.9%), food and beverage and education — rather than concentrated in one kind of arrangement. Medical Device Business Services, Inc. accounts for 65.1% of it on its own, with 13 other manufacturers making up the rest. 2025 is the largest year on record at $1,585, more than ten times the $112 reported in 2019.
Across 38 payments — averaging $55.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medical Device Business Services, Inc.$1K
- AstraZeneca$223
- Johnson & Johnson$150
- Viatris Specialty LLC$114
- Insmed, Inc.$42
- Takeda Pharmaceuticals U.S.A., Inc.$37
- plus $168 from 8 others
What the payments were for
- Travel & lodging$1,19657%
- Food & beverage$88842%
- Education$171%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medical Device Business Services, Inc. | 9 | $1,368 |
| AstraZeneca | 8 | $223 |
| Johnson & Johnson | 3 | $150 |
| Viatris Specialty LLC | 5 | $114 |
| Insmed, Inc. | 2 | $42 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $37 |
| Regeneron Healthcare Solutions, Inc. | 2 | $28 |
| Mylan Specialty L.p. | 1 | $23 |
| Axsome Therapeutics, Inc. | 1 | $22 |
| Amgen | 1 | $21 |
| Actelion Pharmaceuticals US, Inc. | 1 | $20 |
| Harmony Biosciences LLC | 1 | $19 |
| Verona Pharma, Inc. | 1 | $17 |
| United Therapeutics Corporation | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MONARCH$1,241
- Monarch Platform$119
How this compares
$2,101 in reported general payments places this provider in the 65th percentile of 35 pulmonary disease providers in South Dakota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 46 | $34,302 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 11 | $5,877 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 11 | $2,268 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 47 | $1,117 |
| Fluticasone Propionate | 14 | $260 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in Sioux Falls
- Joevasanth DevasahayamSioux Falls$8K
- Matthew TaylorSioux Falls$8K
- Fady JamousSioux Falls$6K
- Rizan HajalSioux Falls$5K
- Kaitlin BranickSioux Falls$5K
- Anna PlemmonsSioux Falls$3K
- Ashraf ElshamiSioux Falls$2K
- John YuSioux Falls$2K
- Rajaganesh RajagopalanSioux Falls$964
- Ross BaconSioux Falls$599
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.